EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Heart Failure in Patients with Congenital Heart Disease After a Cancer Diagnosis

Christina Karazisi iD, Mikael Dellborg, Karin Mellgren, Kok Wai Giang, Kristofer Skoglund, Peter Eriksson, Zacharias Mandalenakis

ESC Heart Failure · 2024

DOI: 10.1002/ehf2.14945 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift ESC Heart Failure, 2024. Verfasst von Christina Karazisi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Heart Defects, Congenital, Neoplasms, Heart Failure. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Swedish Government and County Councils, Swedish Research Council, Hjärt-Lungfonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Individuals with congenital heart disease (CHD) are at an increased risk for cancer. As cancer survival rates improve, the prevalence of late side effects, such as heart failure (HF), is becoming more evident. This study aims to evaluate the risk of developing HF following a cancer diagnosis in patients with CHD, compared with those without CHD and with CHD patients who do not have cancer.

Methods

CHD patients (n = 69 799) and randomly selected non-CHD controls (n = 650 406), born in Sweden between 1952 and 2017, were identified from the Swedish National Health Registers and Total Population Register (excluding those with syndromes and transplant recipients). CHD patients who developed cancer (n = 1309) were propensity score-matched with non-CHD patients who developed cancer (n = 9425), resulting in a cohort of 1232 CHD patients with cancer and 2602 non-CHD controls with cancer (after exclusion of individuals with HF prior to cancer diagnosis). In a separate analysis, CHD patients with cancer were propensity score-matched with CHD patients without cancer (n = 68 490). A total of 1233 CHD patients with cancer and 2257 CHD patients without cancer were included in the study.

Results

Among CHD patients with cancer, 73 (5.9%) developed HF during a mean follow-up time of 8.5 ± 8.7. Comparatively, in the propensity-matched control population, 29 (1.1%) non-CHD cancer patients (mean follow-up time of 7.3 ± 7.5) and 101 (4.5%) CHD patients without cancer (mean follow-up time of 9.9 ± 9.2) developed HF. CHD patients exhibited a significantly higher risk of HF post-cancer diagnosis compared with the non-CHD control group [hazard ratio (HR) 4.39, 95% confidence interval (CI) 2.83–6.81], after adjusting for age at cancer diagnosis and comorbidities. In the analysis between CHD patients with cancer and those without cancer, the results indicated a significantly higher risk of developing HF in CHD patients with cancer (HR 1.53, 95% CI 1.13–2.07).

Conclusions

CHD patients face a more than four-fold increased risk of developing HF after a cancer diagnosis compared with cancer patients without CHD. Among CHD patients, the risk of HF is only modestly higher for those with cancer than for those without cancer. This suggests that the increased HF risk in CHD patients with cancer, relative to non-CHD cancer patients, may be more attributable to CHD itself than to cancer treatment-related side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Defects, CongenitalNeoplasmsHeart FailureHumansMaleFemaleSwedenMiddle AgedRegistriesAdultFollow-Up StudiesPropensity ScoreRisk FactorsIncidenceRetrospective StudiesRisk AssessmentSurvival RateAged

Stichwörter der Autor:innen

cancercancer treatmentcardiotoxicitycardio‐oncologycongenital heart diseaseheart failure

Autor:innen und Institutionen

  • Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Medicine, Geriatrics and Emergency Medicine, Region Västra Götaland, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden.
  • Adult Congenital Heart Disease Unit, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Pediatric Oncology, The Queen Silvia Children's Hospital, Sahlgrenska University Hospital, Gothenburg, Sweden.

ORCID-Profile: Christina Karazisi

Förderung

  • Swedish Government and County Councils
  • Swedish Research Council
  • Hjärt-Lungfonden
  • Barncancerfonden
  • Vetenskapsrådet

Zitieren

APA

Karazisi, C., Dellborg, M., Mellgren, K., Giang, K. W., Skoglund, K., Eriksson, P., & Mandalenakis, Z. (2024). Heart Failure in Patients with Congenital Heart Disease After a Cancer Diagnosis. ESC Heart Failure. https://doi.org/10.1002/ehf2.14945

Vancouver

Karazisi C, Dellborg M, Mellgren K, Giang KW, Skoglund K, Eriksson P, et al. Heart Failure in Patients with Congenital Heart Disease After a Cancer Diagnosis. ESC Heart Failure. 2024. doi:10.1002/ehf2.14945

BibTeX
@article{Karazisi2024,
  author = {Karazisi, Christina and Dellborg, Mikael and Mellgren, Karin and Giang, Kok Wai and Skoglund, Kristofer and Eriksson, Peter and Mandalenakis, Zacharias},
  title = {Heart Failure in Patients with Congenital Heart Disease After a Cancer Diagnosis},
  journal = {ESC Heart Failure},
  year = {2024},
  doi = {10.1002/ehf2.14945}
}
Kostenlos starten →